Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

J. A. McCaffrey, S. Hilton, M. Mazumdar, S. Sadan, W. K. Kelly, H. I. Scher, D. F. Bajorin

Research output: Contribution to journalArticlepeer-review

344 Scopus citations


Purpose: A phase II trial of docetaxel was conducted to assess its efficacy and toxicity in patients with advanced transitional-cell carcinoma (TCC) who had failed to respond to prior cisplatin-based therapy. Patients and Methods: Thirty assessable patients who had failed to respond to or relapsed after one prior cisplatin-containing regimen were treated with docetaxel 100 mg/m2 over 1 hour, every 21 days. All patients were premedicated with dexamethasone and diphenhydramine to reduce allergic reactions. Reductions of subsequent doses were made for severe hematologic toxicity. Prophylactic hematopoietic growth factors were not used. Results: Four of 30 patients (13.3%; 95% confidence interval [CI], 3.8% to 30.7%) demonstrated a partial response (PR), with durations of response ranging from 3 to 8 months. The estimated median survival duration for all patients is 9 months (95% CI, 6 to 12 months) with a median follow-up time of 14 months (range, 1 to 27). Hematologic toxicity included anemia, thrombocytopenia, neutropenia, and febrile neutropenia. Nonhematologic toxicity included alopecia and mucositis. Fluid retention was not observed and cutaneous toxicity was mild and infrequent. Dose reductions were necessary for adverse events in 18 patients (60%). Conclusion: Docetaxel is an active single agent in previously treated patients with TCC of the urothelial tract. Therapy was well tolerated in this patient population but myelosuppression was frequent. Further study in previously untreated patients, both alone and in combination, is warranted.

Original languageEnglish
Pages (from-to)1853-1857
Number of pages5
JournalJournal of Clinical Oncology
Issue number5
StatePublished - May 1997
Externally publishedYes


Dive into the research topics of 'Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma'. Together they form a unique fingerprint.

Cite this